Linkage of bacterial capsular polysaccharides to proteins to create conjugate vaccines has had a dramatic impact on the health of children. Although unconjugated polysaccharides are poorly immunogenic in infants and some older children and adults, their covalent coupling with proteins stimulates T cell dependent antigenic recognition that profoundly enhances immunogenicity. In the decade since the introduction and widespread use of *Haemophilus influenzae* type b polysaccharide conjugate vaccines in the United States, invasive *H influenzae* infections have become a rarity in childhood. Similarly, the conjugation of polysaccharides of *Streptococcus pneumoniae* to a derivative of diphtheria toxoid and the addition of pneumococcal conjugate vaccine to infant immunisation schedules carries with it promise for a similar decline in the incidence of invasive pneumococcal disease in paediatric patients.

**THE RATIONALE FOR GBS POLYSACCHARIDE–PROTEIN CONJUGATE VACCINES**

A protective role for antibodies to the capsular polysaccharide (CPS) of type III GBS was predicted in the 1970s by Baker and Kasper. These investigators showed that infants with invasive early or late onset GBS disease were born to mothers with very low levels of III CPS specific antibodies in sera at delivery. The finding that human sera containing a sufficient concentration of CPS specific IgG promoted efficient opsonisation and phagocytosis in vitro and provided protection from lethal experimental infection affirmed the importance of capsular serotype specific antibodies. This information, combined with that showing the efficacy of pneumococcal polysaccharide vaccine in adults, suggested that active immunisation of pregnant women with purified GBS polysaccharides could protect neonates and young infants. The premise was that if vaccination elicited protective levels of antibodies in childbearing age women, placental passage of these GBS CPS specific antibodies would protect neonates throughout the period of disease risk for invasive GBS infection (for example, the first 2–3 months of life).

Once the GBS three major serotypes that caused invasive GBS disease (Ia, II, and III) were structurally and immunochemically defined, there was a sense of expectation among investigators in the field. The first candidate GBS vaccine, a purified type III CPS, underwent phase 1 testing in healthy adults in 1978; subsequently type Ia and II CPS vaccines were studied. By contrast to the excellent immunogenicity observed in adults immunised with multivalent pneumococcal polysaccharide vaccine, type Ia, II, and III polysaccharides, while well tolerated, had uneven immunogenicity. Most adults (nearly 90%), it was discovered, had very low preimmunisation serum concentrations of CPS specific antibodies. These low levels, presumably indicating immunologic naivety to GBS polysaccharides, predicted a poor immune response in many, so that only 40% and 60%, respectively, developed significant increases in specific antibodies after immunisation with type Ia and III polysaccharides. By contrast, 88% of those immunised with type II CPS responded. In the few adults who presumably had been “primed” to GBS polysaccharides or related antigens (indicated by moderately increased serum
concentrations of CPS specific antibodies), immunisation with type Ia, II, and III polysaccharides elicited brisk immune responses in nearly 100%.

The trials with GBS polysaccharide vaccines verified the feasibility of immunisation as an approach to prevent GBS disease and revealed the need to develop candidate vaccines with improved immunogenicity. One encouragement to the ultimate success of a GBS vaccine programme was the first study conducted in pregnant women. Among responders to a type III GBS CPS vaccine administered at about 31 weeks of gestation, 90% had infants with substantial levels of III CPS specific antibodies in cord sera that promoted opsonisation and killing of type III GBS in vitro; this functional activity of infant sera persisted in the majority until age 3 months. Thus, in concept, maternal immunisation with an optimally immunogenic GBS vaccine during the third trimester should protect neonates and young infants from invasive GBS infection during the age of risk.\(^7\)

THE CURRENT STATUS OF GBS CONJUGATE VACCINES

In the early 1990s a new GBS serotype, type V, emerged among cases in the USA and in other countries. A recent multiplicity active surveillance study of invasive GBS disease performed in a racially and ethnically diverse cohort of pregnant women and neonates noted that type V accounted for 23% and 14%, respectively, of maternal and early onset neonatal cases.\(^11\) The emergence of type V and an increasing number of nontypeable GBS isolates from colonised adults underscores the importance of ongoing epidemiologic investigations in formulating an appropriate multivalent GBS vaccine. Taken together, types Ia, III, and V GBS now account for at least 75%, and five serotypes (Ia, Ib, II, III, and V) for virtually 100% of GBS disease in infants and adults.\(^11\)

Development of the first GBS conjugate vaccine, type III polysaccharide–tetanus toxoid, was driven by its prominence among infant isolates, especially those with meningitis and late onset infection with any clinical presentation. This type III CPS was covalently linked to monomeric tetanus toxoid using reductive amination coupling chemistry. CPS was covalently linked to monomeric tetanus toxoid using late onset infection with any clinical presentation. This type III polysaccharide–tetanus toxoid, was driven by its prominence of three dosages, uncoupled III CPS, or placebo (saline). \(^11\) The trials with GBS polysaccharide vaccines verified the feasibility of immunisation as an approach to prevent GBS disease and revealed the need to develop candidate vaccines with improved immunogenicity. One encouragement to the ultimate success of a GBS vaccine programme was the first study conducted in pregnant women. Among responders to a type III GBS CPS vaccine administered at about 31 weeks of gestation, 90% had infants with substantial levels of III CPS specific antibodies in cord sera that promoted opsonisation and killing of type III GBS in vitro; this functional activity of infant sera persisted in the majority until age 3 months. Thus, in concept, maternal immunisation with an optimally immunogenic GBS vaccine during the third trimester should protect neonates and young infants from invasive GBS infection during the age of risk.\(^7\)

### Table 1: Group B streptococcal CPS–TT conjugate vaccines

<table>
<thead>
<tr>
<th>GBS vaccine</th>
<th>Approximate CPS concentration (µg/ml)</th>
<th>Proportion of adults with greater than fourfold rises in CPS specific IgG at 8 weeks</th>
<th>GMC (µg/ml) of CPS specific IgG at 8 weeks</th>
<th>Estimated percent absolute rise in the USA by GBS serotype†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ia-TT*</td>
<td>15</td>
<td>80%</td>
<td>18.3 (6.0 to 55.4)</td>
<td>25</td>
</tr>
<tr>
<td>Ib-TT*</td>
<td>16</td>
<td>80%</td>
<td>11.1 (3.3 to 37.0)</td>
<td>5</td>
</tr>
<tr>
<td>III-TT*</td>
<td>4</td>
<td>87%</td>
<td>11.2 (6.1 to 20.8)</td>
<td>5</td>
</tr>
<tr>
<td>V-TT*</td>
<td>13</td>
<td>93%</td>
<td>2.7 (1.0 to 7.8)</td>
<td>50</td>
</tr>
<tr>
<td>VTT*</td>
<td>10</td>
<td>93%</td>
<td>5.5 (1.5 to 20.0)</td>
<td>15</td>
</tr>
</tbody>
</table>

*Data from reference 1a (Ia and Ib), 15 (III), and 16 and 17 (III). Unpublished observations for type V.
†Data from references 10 and 11.

Dose-response testing has been performed for Ia, Ib, II, III, and V CPS-TT conjugates to determine the minimum dose that could be used in a multivalent vaccine (table 1). Such data are necessary to minimise the total amount of polysaccharide needed to stimulate a protective level of immunity and the rate of local reactions that appear to depend primarily on total tetanus carrier dose. Immune responses to GBS conjugates, with the exception of type V, are dose dependent. Doses of ~4 µg for type Ia CPS, 10 µg for type Ib, and ~15 µg for type III, and III CPS have elicited greater than fourfold increases in CPS specific IgG in 80–93% of volunteers eight weeks post-immunisation. For each serotype, conjugation has enhanced significantly immunogenicity when compared to uncoupled polysaccharides. Vaccine responses generally reach a peak four to eight weeks after immunisation and then decline. At one year after immunisation, the geometric mean concentration (GMC) of antibody is approximately 50% of the peak level. For example, subjects immunised with a 15 µg dose of type Ia CPS-TT have a GMC of 18.3 µg/ml at eight weeks after immunisation and 9.1 µg/ml at one year.\(^7\) Based on limited data at two years after immunisation, the GMC is still well above baseline, suggesting that as with other conjugate vaccines, the response to GBS conjugate vaccines is durable (Baker and colleagues;\(^14\) also Baker et al, unpublished observations). Functional activity has been tested in vitro with an opsonophagocytosis assay. For each serotype, positive correlations exist between killing of homologous GBS strains by human neutrophils after opsonisation by complement and concentration of conjugate vaccine induced CPS specific IgG.\(^13,16\) These findings suggest that GBS conjugates of a design similar to those already tested will be effective in GBS disease prevention. Table 1 summarises the immune responses to theoretically optimal dosages of each GBS conjugate vaccine tested in healthy adults and the proportion of disease in pregnant women and young infants (early and late onset disease) caused by the five serotypes. The magnitude of immune responses suggests that a single dose of a pentavalent GBS conjugate vaccine might be expected to have an efficacy of nearly 90%.
With a pentavalent vaccine as the goal, preliminary evaluation of a combination of types II-TT and III-TT vaccines has been conducted. This bivalent II/III CPS-TT conjugate vaccine was well tolerated in healthy adults and no immune interference was noted when compared to vaccinees who received a monovalent II-TT or III-TT conjugate. The bivalent vaccine stimulated immune responses comparable to those elicited by either of the monovalent conjugates. Another question of importance is whether a single dose of GBS conjugate vaccine will elicit an optimal response among a majority of recipients or whether a "booster" will be required. To address this, a group of healthy adults were given a second dose of III-TT vaccine 21 months after their initial immunisation. No increase in reactogenicity was observed, but the GMC of III CPS specific IgG eight weeks after the second dose was similar to that noted after the initial dose, indicating no discernable booster effect for the group as a whole. A small proportion of adults, some of these with the lowest preimmunisation antibody concentrations, did exhibit a "booster" response. Further studies will be required to prove the hypothesis that these individuals were truly naïve to the antigen, were "primed" with the first dose, and subsequently had an optimal response.

Two lots of type V conjugate vaccine have been tested in phase I clinical trials (Baker CJ, unpublished observations). The first used TT and the second the mutant diphtheria toxin, cross reactive material 197 (CRM₃₅). The two conjugates were similarly well tolerated. Type V-TT recipients had slightly higher CPS specific IgG levels in their sera following immunisation than the V-CRM₃₅ group, but the differences were not significant. These findings, using CRM₃₅, as a protein carrier, are important because they affirm that more than one carrier can recruit the T cell help needed for an adequate immune response to a GBS polysaccharide.

As with the uncoupled GBS polysaccharide, a phase I trial in women at 32–34 weeks of gestation has just been completed. After randomisation, III-TT conjugate (12.5 µg dose of III CPS) or saline placebo was administered to 20 and 10 women, respectively. III CPS specific IgG concentrations were determined in maternal sera at delivery (at a mean of 8.3 weeks after immunisation), infant cord sera, and in sera obtained from infants at 1 and 2 months of age. GMCs in delivery sera from immunised women were significantly increased from preimmunisation values and correlated well ($r = 0.93$) with infant cord values. The actual GMCS in sera from infants of vaccinated women were 3.7 and 2.2 µg/ml, respectively, at 1 and 2 months of age. Sera from these infants of vaccinated women uniformly promoted opsonisation of type III GBS and killing by neutrophils in vitro. Thus, conjugate vaccine induced III CPS specific IgG was efficiently translocated to the neonate and functions well in vitro, suggesting that a multivalent GBS conjugate vaccine has the potential for prevention of late as well as of early onset infant GBS disease, and possibly to effect a decrease in maternal potential for prevention of late as well as of early onset infant GBS disease, and possibly to effect a decrease in maternal

BARRIERS TO LICENSURE OF GBS CONJUGATE VACCINES

Over two decades of investigation verifies the notion that maternal immunisation with a multivalent GBS conjugate vaccine is a valid approach to prevention of GBS disease in infancy. Published data indicate that candidate GBS polysaccharide–tetanus toxoid conjugates are safe in adults and elicit antibodies well above what is likely to be passively protective for neonates and young infants. The remaining scientific issue that must be answered for licensure is documentation of the efficacy of a GBS conjugate vaccine in a phase 3 trial. In order to facilitate such a trial, the formation of a corporate partnership with a pharmaceutical company would be desirable. There are concerns regarding such an undertaking. One obvious roadblock is a longstanding hesitancy to confront liability issues that surround immunisation of pregnant women. However, millions of doses of tetanus toxoid have been given to pregnant women without adverse effects. Since the GBS polysaccharides are simple sugars, it is difficult to conceive of their having other than a salutary effect on pregnant women and their fetuses when administered early in the third trimester. It has been suggested that an injury compensation programme, similar to those in effect for childhood immunisations, should be developed for maternal immunisation programmes to create an environment conducive for providers and encouraging to the vaccine industry. The formation, in the 1990s, of such public advocacy groups as the Group B Strep Association in the United States and the Canadian Group B Strep Association in Canada have fostered media attention on the importance of preventing vaccine prevention of GBS infection—a reality. While other target populations, such as nonpregnant, childbearing age women and even adolescents, could be considered for immunisation, efficacy testing would not be practical in such populations. However, nonpregnant adults with defined medical conditions such as diabetes mellitus, chronic liver disease, and malignancy, or those more than 65 years of age would be reasonable target populations given their current invasive GBS disease burden. To date, almost no information exists regarding potentially protective CPS specific antibodies in these patients, whether other immune defence abnormalities render protective levels functionally inadequate, and if GBS conjugate are adequately immunogenic. The scientific evidence for maternal immunisation to prevent perinatal GBS disease is compelling. If perinatal GBS disease is to become, as with H influenzae type b disease in infants, a rarity, the time for pharmaceutical industry leadership is now.

-----

Authors’ affiliations
C J Baker, M S Edwards, Section of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA

REFERENCES
A 13 year old adolescent girl presented with vague abdominal pain of a week’s duration. The pain was not associated with vomiting, fever, or weight loss. She was thin built and had mild pallor. Examination of the abdomen revealed a large curvilinear hard intraperitoneal mass, occupying the epigastrium and left hypochondriac regions (fig 1). Abdominal skigram and ultrasonography were suggestive of gastric bezoar. A history of pica and ingestion of hair strands was obtained subsequently. Laparotomy was performed and a huge trichobezoar was removed from the stomach in toto successfully (fig 2).

Bezoar is a concretion of material in the lumen of the digestive tract ingested over time. Four types of bezoar have been described: phyto-bezoar (vegetable material); trichobezoar (hair); lactobezoar; and miscellaneous. The presenting symptoms are abdominal pain, vomiting, early satiety, anorexia, weight loss, abdominal mass, and rarely gastric obstruction. Abdominal skigram and upper gastrointestinal contrast study are diagnostic. Therapeutic options consist of endoscopic fragmentation and removal, and dissolution with substances such as papain, saline, acetylcysteine, and cellulase. Extracorporeal shock wave lithotripsy and laser therapy have been described as therapeutic modalities. Trichobezoars virtually always require surgical removal. They are often found in emotionally disturbed patients and warrant a psychiatric evaluation to prevent recurrence.

B Sundaram, N Selvarajan, S Somu, A N Kamalanathan
Kanchi Kamakoti CHILLS Trust Hospital,
12A Nageswara Road, Nungambakkam, Chennai,
16, India; akamalanathan@rediffmail.com

References
Group B streptococcal conjugate vaccines

C J Baker and M S Edwards

Arch Dis Child 2003 88: 375-378
doi: 10.1136/adc.88.5.375

Updated information and services can be found at:
http://adc.bmj.com/content/88/5/375

These include:

References
This article cites 23 articles, 10 of which you can access for free at:
http://adc.bmj.com/content/88/5/375#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Immunology (including allergy) (2018)
Vaccination / immunisation (334)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/